2. Academic Validation
  3. FGF6 promotes cardiac repair after myocardial infarction by inhibiting the Hippo pathway

FGF6 promotes cardiac repair after myocardial infarction by inhibiting the Hippo pathway

  • Cell Prolif. 2022 May;55(5):e13221. doi: 10.1111/cpr.13221.
Zhicheng Hu 1 2,  Peng Chen 1,  Linlin Wang 3,  Yu Zhu 4,  Gen Chen 2 5,  Yunjie Chen 6,  Zhenyu Hu 2,  Lin Mei 2,  Weijing You 7,  Weitao Cong 2,  Litai Jin 2,  Xu Wang 2,  Yang Wang 4,  Xueqiang Guan 1
Affiliations

Affiliations

  • 1 Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, P.R. China.
  • 2 School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, P.R. China.
  • 3 Children's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, P.R. China.
  • 4 Department of Histology and Embryology, Institute of Neuroscience, Wenzhou Medical University, Wenzhou, P.R. China.
  • 5 College of Pharmacy, Chonnam National University, Gwangju, South Korea.
  • 6 Department of Pharmacy, Ningbo first Hospital, Ningbo, PR China.
  • 7 School of Medical Technology, Ningbo College of Health Sciences, Ningbo, PR China.
PMID: 35355356 DOI: 10.1111/cpr.13221
Abstract

Objectives: Myocardial infarction (MI) commonly occurs in patients with coronary artery disease and have high mortality. Current clinical strategies for MI still limited to reducing the death of myocardial cells but failed to replace these cells. This study aimed to investigate the role of Fibroblast Growth Factor 6 (FGF6) in enhancing the proliferative potential of cardiomyocytes (CMs) after ischemic injury via the Hippo pathway.

Materials and methods: Expression of FGF6 protein was analysed in mice with MI induced by ligation of the left anterior descending coronary artery. Activation of the Hippo pathway and the proliferation potential were examined in ischemic CMs, treated with FGF6 protein or transfected with an adeno-virus carrying FGF6 sh-RNA. Immunofluorescence staining and western blotting were performed to assess the relationship between FGF6 and the Hippo pathway.

Results: We found that FGF6 expression was significantly increased in the MI mouse model. Knockdown of FGF6 synthesis resulted in poorer heart function after MI. By contrast, treatment with recombinant human FGF6 protein improved heart function, reduced infarct size, and promoted cardiac repair. Additionally, FGF6 restrains the activation of the Hippo pathway and subsequently promotes nuclear accumulation of YAP. This was largely counteracted by treatment with extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126.

Conclusion: FGF6 inhibits the Hippo pathway via ERK1/2, and facilitates nuclear translocation of YAP, and thereby promotes cardiac repair after MI.

Figures
Products